Nektar Therapeutics sell JPMorgan Chase & Co.
Start price
20.11.23
/
50%
€0.47
Target price
20.11.24
-
Performance (%)
211.49%
Price
03.05.24
€1.46
Summary
This prediction is currently active. The price for Nektar Therapeutics has massively increased, which is bad news for the SELL prediction by JPMorgan_Chase___Co_. This prediction currently runs until 20.11.24. The prediction end date can be changed by JPMorgan_Chase___Co_ at any time. JPMorgan_Chase___Co_ has 50% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Nektar Therapeutics | 19.121% | 19.121% |
| iShares Core DAX® | -0.922% | -1.993% |
| iShares Nasdaq 100 | 0.371% | -0.868% |
| iShares Nikkei 225® | 2.224% | -5.187% |
| iShares S&P 500 | -0.026% | -0.918% |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Discuss Nektar Therapeutics
Nektar Therapeutics (NASDAQ: NKTR) had its "underweight" rating re-affirmed by analysts at JPMorgan Chase & Co..
Ratings data for NKTR provided by MarketBeat